Patents Assigned to Quadrant Healthcare
-
Publication number: 20070026081Abstract: Microparticles comprising or consisting of a therapeutic agent having a particle density of at least 80% of the solid agent and a shape factor of 1 to 5. The microparticles may be produced by spray drying and may be used in needleless injection.Type: ApplicationFiled: October 2, 2006Publication date: February 1, 2007Applicant: Quadrant Healthcare (UK) LimitedInventor: Nicholas Osborne
-
Patent number: 6623722Abstract: A process for forming microcapsules comprising (i) providing a solution of a protein in an aqueous solvent and (ii) spraying the said solution into a gas such that the aqueous solvent evaporates, thereby forming hollow microcapsules, characterised in that the aqueous solution contains a liquid of greater volatility than water. The protein is preferably albumin and the volatile liquid is preferably ethanol. The microcapsules may be used as ultrasound echogenic contrast agents.Type: GrantFiled: February 13, 1998Date of Patent: September 23, 2003Assignee: Quadrant Healthcare (UK) LimitedInventors: Nicholas Osborne, Andrew Derek Sutton, Richard Alan Johnson
-
Publication number: 20030133876Abstract: Microspheres are prepared by a process comprising the steps of (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microspheres and (ii) reducing the water-solubility of at least the outside of the intermediate microspheres. Suitable wall-forming materials include proteins such as albumin and gelatin. The microsphere have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilisation and cross-linking of the wall-forming material allows novel microsphere preparations to be produced. In particular, the microspheres may be 15-20 &mgr;m, targeted to selected areas of the body or of prolonged life in the circulation.Type: ApplicationFiled: June 21, 2002Publication date: July 17, 2003Applicant: Quadrant Healthcare (UK) Limited, a member of the Elam Group of CompaniesInventors: Andrew D. Sutton, Richard A. Johnson
-
Patent number: 6569405Abstract: Microcapsules are prepared by a process comprising the steps of (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microcapsules and (ii) reducing the water-solubility of at least the outside of the intermediate microcapsules. Suitable wall-forming materials include proteins such as albumin and gelatin. The microcapsules have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilization and cross-linking of the wall-forming material allows novel microsphere preparations to be produced.Type: GrantFiled: September 28, 1999Date of Patent: May 27, 2003Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew D. Sutton, Richard A. Johnson, Peter J. Senior, David Heath
-
Publication number: 20020197325Abstract: Microparticles comprising or consisting of a therapeutic agent have a particle density of at least 80% of the solid agent and a shape factor of 1 to 5. The microparticles may be produced by spray drying and may be used in needleless injection.Type: ApplicationFiled: March 2, 2001Publication date: December 26, 2002Applicant: Quadrant Healthcare (UK) LimitedInventor: Nicholas D. Osborne
-
Patent number: 6495527Abstract: Removal of lipid from lipid-bound protein such as human serum albumin to produce defatted protein enhances ability of the protein to bind therapeutic agents for use as a carrier for the therapeutic agent. The defatted protein may be reloaded with cationic and/or anionic lipids such as fatty acids, e.g. DC-Chol, to modify charge, hydrophilicity or hydrophobicity of the defatted protein to further enhance ability of the defatted protein to bind a therapeutic agent. A reloaded lipid itself may be a therapeutic agent. The defatted protein may be produced as microparticles by spray-drying. Defatting can be achieved by removing fatty acids with acidified activated charcoal, or by solvent extraction. A complex of DNA and a microparticle of defatted protein containing a cationic or anionic lipid molecule can be used for gene therapy. Defatted albumin may be reloaded with aminocaprylic acid to provide a microparticle for binding DNA for parenteral delivery.Type: GrantFiled: January 22, 1999Date of Patent: December 17, 2002Assignee: Quadrant Healthcare, Ltd.Inventors: Roy Harris, Nicholas David Osborne
-
Patent number: 6468782Abstract: This invention provides methods of drying and stabilizing prokaryotic cells, and the compositions obtained thereby. The cells are first cultured or incubated under conditions sufficient to induce intracellular trehalose, suspended in a stabilizing solution and dried to form a solid glass. The resulting product is storage-stable at room temperature, showing little viability loss on storage.Type: GrantFiled: December 4, 1997Date of Patent: October 22, 2002Assignee: Quadrant Healthcare (UK) LimitedInventors: Alan G. Tunnacliffe, David T. Welsh, Bruce J. Roser, Kamaljit S. Dhaliwal, Camilo Colaco
-
Patent number: 6451349Abstract: Microparticles, obtainable by spray-drying a substantially pure solution of a therapeutic agent, consist essentially of the agent having its therapeutic activity when administered to the lung. In a preferred embodiment the agent is insulin.Type: GrantFiled: June 29, 1999Date of Patent: September 17, 2002Assignee: Quadrant Healthcare (UK) LimitedInventors: Stuart Robinson, Susan Stewart Smith
-
Patent number: 6416739Abstract: Microcapsules having a wall thickness of no more than 500 nm, and a bulk density of no more than 0.2 g.cm−3, are suitable for therapeutic or diagnostic use. They are aerodynamically light, and can be used for delivery to the lung, or diagnosis by ultrasound.Type: GrantFiled: July 20, 2000Date of Patent: July 9, 2002Assignee: Quadrant Healthcare (UK) LimitedInventors: Cheryl Vanessa Rogerson, Nicholas David Osborne
-
Patent number: 6416741Abstract: Microspheres are prepared by a process comprising (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microspheres and (ii) reducing the water-solubility of at least the outside of the intermediate microspheres. Suitable wall-forming materials include proteins such as albumin and gelatin. The microspheres have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilisation and cross-linking of the wall-forming material allows novel microsphere preparations to be produced. In particular, the microspheres may be 15-20 &mgr;m, targeted to selected areas of the body or of prolonged life in the circulation.Type: GrantFiled: September 3, 1999Date of Patent: July 9, 2002Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew Derek Sutton, Richard Alan Johnson
-
Patent number: 6348186Abstract: Microspheres are prepared by a process comprising the steps of (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microspheres and (ii) reducing the water-solubility of at least the outside of the intermediate microspheres. Suitable wall-forming materials include proteins such as albumin and gelatin. The microsphere have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilisation and cross-linking of the wall-forming material allows novel microsphere preparations to be produced. In particular, the microspheres may be 15-20 &mgr;m, targeted to selected areas of the body or of prolonged life in the circulation.Type: GrantFiled: June 5, 1995Date of Patent: February 19, 2002Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew Derek Sutton, Richard Alan Johnson
-
Patent number: 6344182Abstract: Microspheres are prepared by a process comprising the steps of (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microspheres and (ii) reducing the water-solubility of at least the outside of the intermediate microspheres. Suitable wall-forming materials include proteins such as albumin and gelatin. The microsphere have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilisation and cross-linking of the wall-forming material allows novel microsphere preparations to be produced. In particular, the microspheres may be 15-20 &mgr;m, targeted to selected areas of the body or of prolonged life in the circulation.Type: GrantFiled: June 28, 1995Date of Patent: February 5, 2002Assignee: Quadrant Healthcare (UK) LImitedInventors: Andrew Derek Sutton, Richard Alan Johnson
-
Patent number: 6113948Abstract: Soluble microparticles comprising fibrinogen or thrombin, in free-flowing form. These microparticles can be mixed to give a dry powder, to be used as a fibrin sealant that is activated only at a wound site.Type: GrantFiled: May 19, 1997Date of Patent: September 5, 2000Assignee: Quadrant HealthcareInventors: David Heath, Sarah Margaret Middleton
-
Patent number: 6068600Abstract: A method of generating an ultrasound image comprising the steps of (i) introducing into the location to be imaged an ultrasound contrast agent obtained by spraying a solution or suspension of a wall forming material into a heated gas to form hollow microcapsules, (ii) exposing the microcapsules to ultrasound energy at an insonation frequency of less than 3.5 MHz and (iii) creating an image based on the scattering of the ultrasound energy by the microcapsules.Type: GrantFiled: December 6, 1996Date of Patent: May 30, 2000Assignee: Quadrant Healthcare (UK) LimitedInventors: Richard Alan Johnson, Paulus Antonius van der Wouw
-
Patent number: 6022525Abstract: Microcapsules are prepared by a process comprising the steps of (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microcapsules and (ii) reducing the water-solubility of at least the outside of the intermediate microcapsules.Suitable wall-forming materials include proteins such as albumin and gelatin.The microcapsules have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilisation and cross-linking of the wall-forming material allows novel microsphere preparations to be produced.Type: GrantFiled: August 22, 1995Date of Patent: February 8, 2000Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew D. Sutton, Richard A. Johnson, Peter J. Senior, David Heath
-
Patent number: 6015546Abstract: Microcapsules are prepared by a process comprising the steps of (i) spray-drying a solution or dispersion of a wall-forming material in order to obtain intermediate microcapsules and (ii) reducing the water-solubility of at least the outside of the intermediate microcaspsules.Suitable wall-forming materials include proteins such as albumin and gelatin.The microcapsules have walls of 40-500 nm thick and are useful in ultrasonic imaging. The control of median size, size distribution and degree of insolubilization and cross-linking of the wall-forming material allows novel microsphere preparations to be produced.Type: GrantFiled: June 5, 1995Date of Patent: January 18, 2000Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew Derek Sutton, Richard Alan Johnson
-
Patent number: 5993805Abstract: Microparticles of a water-soluble material, which are smooth and spherical, and at least 90% of which have a mass median particle size of 1 to 10 .mu.m, and which carry a therapeutic or diagnostic agent can successfully be used in dry powder inhalers to deliver the said agent.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew D. Sutton, Richard A. Johnson, Peter J. Senior, David Heath
-
Patent number: 5977313Abstract: Platelet substitutes, comprising fibrinogen, or analogous products useful in therapy, which further comprise an insoluble carrier to which is bound an essentially non-degraded active protein including the sequence Arg-Gly-Asp. Such conjugates can be made by a conjugation process comprising 0.01 to 2.5% by weight active fibrinogen, and no more that 50% inactive fibrinogen.Type: GrantFiled: October 17, 1997Date of Patent: November 2, 1999Assignee: Quadrant Healthcare LimitedInventors: David Heath, Sarah Margaret Middleton, Roy Harris, Nicola Jane Church
-
Patent number: 5955108Abstract: A sterile powder comprising microparticles, 0.1 to 50 .mu.m in diameter, obtainable by spray-drying and cross-linking a water-soluble material having free functional groups, is characterized in that the microparticles are hydrophilic, can be reconstituted in water to give a monodisperse suspension, and have retained said groups available for derivatization. The particles are linked to drugs or other functional molecules, and used as vehicles in therapy.Type: GrantFiled: June 16, 1997Date of Patent: September 21, 1999Assignee: Quadrant Healthcare (UK) LimitedInventors: Andrew Derek Sutton, Richard Alan Johnson